Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04763876 · ClinicalTrials.gov registry record · Phase 4

Intramuscular Ketorolac at Two Single-Dose Regimens

A Phase 4 study, sponsored by William Beaumont Army Medical Center.

Completed
Registry status
Phase 4
Development phase
110
Enrollment target

NCT04763876 is a Phase 4 study that has completed, run by William Beaumont Army Medical Center. The registered enrollment target is 110 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04763876, a Phase 4 study, has completed, sponsored by William Beaumont Army Medical Center.

COMPLETED
Registry status
Phase 4
Development phase
110 participants
Enrollment target

Study Summary

The purpose of this study was to evaluate a single 15 mg intramuscular (IM) dose of ketorolac for analgesic non-inferiority versus a single 60 mg IM dose for the treatment of acute MSK pain in a military emergency department (ED) that services Department of Defense (DoD), Department of Veteran Affairs (VA), and foreign military beneficiaries

Interventions

  • DRUG Ketorolac Injection 15 mg
  • DRUG Ketorolac Injection 60 mg

Trial Details

FieldValue
Enrollment Target 110 participants
Start Date 2020-06-27
Est. Completion 2021-02-04
Phase Phase 4

What the Registry Record Tells You About NCT04763876

The ClinicalTrials.gov registry entry for NCT04763876 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is William Beaumont Army Medical Center, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Ketorolac Injection 15 mg is the first listed.

NCT04763876 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04763876 about?

NCT04763876 is a clinical study titled "Intramuscular Ketorolac at Two Single-Dose Regimens". The purpose of this study was to evaluate a single 15 mg intramuscular (IM) dose of ketorolac for analgesic non-inferiority versus a single 60 mg IM dose for the treatment of acute MSK pain in a military emergency department (ED) that services Department of Defense (DoD), Department of Veteran Affai...

What is the current status of trial NCT04763876?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 110 participants. The study started on 2020-06-27. Estimated completion is 2021-02-04.

What interventions are being tested in trial NCT04763876?

The interventions under investigation include: Ketorolac Injection 15 mg (DRUG), Ketorolac Injection 60 mg (DRUG).

Who is sponsoring clinical trial NCT04763876?

This trial is sponsored by William Beaumont Army Medical Center, which has 4 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.